Due to clinical impact, in the new ICC system, a new subgroup was generated which constitutes a separate entity within the group of myeloid neoplasms with mutated TP53 which includes MDS, MDS/AML and AML with mutated TP53 [9, 22, 23]. The gene discussed is TP53; the disease is myeloid neoplasm.